Carsten  Brunn net worth and biography

Carsten Brunn Biography and Net Worth

Dr. Carsten Brunn, Ph.D. is President, Chief Executive Officer, Director of the Company, effective December 1, 2018. He has served as our President, Chief Executive Officer and member of our Board of Directors since December 2018. Prior to joining Selecta Biosciences, Inc., Dr. Brunn was the President of Pharmaceuticals for the Americas Region and a member of the Global Pharmaceutical Executive Committee at Bayer AG, a pharmaceutical company, since January 2017. Previously, he served as President of Bayer Pharmaceuticals in Japan, a role he held since March 2013. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing innovative pharmaceutical companies in Japan. Dr. Brunn has held a number of senior leadership positions at Eli Lilly, Novartis, Basilea and Bausch and Lomb in Europe, Asia and the United States. He currently serves on the board of directors of the Biotechnology Innovation Organization (BIO). Dr. Brunn holds a Ph.D. in Chemistry from the University of Hamburg and a Master of Science in Pharmaceutical Sciences from the University of Freiburg. He also studied at the University of Washington under a research scholarship and completed his executive education at London Business School. Dr. Brunn's experience as a senior executive of life sciences companies and knowledge of the pharmaceutical and biotechnology industries contributed to our Board of Directors' conclusion that he should serve as a director of the Company.

What is Carsten Brunn's net worth?

The estimated net worth of Carsten Brunn is at least $0.00 as of September 25th, 2023. Dr. Brunn owns 783,081 shares of Selecta Biosciences stock worth more than $0 as of January 2nd. This net worth approximation does not reflect any other investments that Dr. Brunn may own. Additionally, Dr. Brunn receives a salary of $914,660.00 as CEO at Selecta Biosciences. Learn More about Carsten Brunn's net worth.

How old is Carsten Brunn?

Dr. Brunn is currently 52 years old. There are 5 older executives and no younger executives at Selecta Biosciences. Learn More on Carsten Brunn's age.

What is Carsten Brunn's salary?

As the CEO of Selecta Biosciences, Inc., Dr. Brunn earns $914,660.00 per year. Learn More on Carsten Brunn's salary.

How do I contact Carsten Brunn?

The corporate mailing address for Dr. Brunn and other Selecta Biosciences executives is 65 Grove Street, Watertown MA, 02472. Selecta Biosciences can also be reached via phone at (617) 923-1400 and via email at [email protected]. Learn More on Carsten Brunn's contact information.

Has Carsten Brunn been buying or selling shares of Selecta Biosciences?

Carsten Brunn has not been actively trading shares of Selecta Biosciences within the last three months. Most recently, Carsten Brunn sold 2,932 shares of the business's stock in a transaction on Monday, September 25th. The shares were sold at an average price of $1.06, for a transaction totalling $3,107.92. Following the completion of the sale, the chief executive officer now directly owns 783,081 shares of the company's stock, valued at $830,065.86. Learn More on Carsten Brunn's trading history.

Who are Selecta Biosciences' active insiders?

Selecta Biosciences' insider roster includes Timothy Barabe (Director), Carsten Brunn (CEO), Nishan de Silva (Director), Timothy Springer (Director), Kevin Tan (CFO), and Peter Traber (Insider). Learn More on Selecta Biosciences' active insiders.

Carsten Brunn Insider Trading History at Selecta Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2023Sell2,932$1.06$3,107.92783,081View SEC Filing Icon  
1/4/2023Sell27,597$1.13$31,184.61799,486View SEC Filing Icon  
12/5/2022Sell4,522$1.33$6,014.26544,283View SEC Filing Icon  
9/28/2022Sell2,692$1.66$4,468.72537,867View SEC Filing Icon  
1/5/2022Sell13,597$3.09$42,014.73View SEC Filing Icon  
12/10/2021Sell17,196$2.99$51,416.04View SEC Filing Icon  
12/2/2021Sell4,746$2.96$14,048.16View SEC Filing Icon  
10/13/2021Sell15,313$4.39$67,224.07View SEC Filing Icon  
12/2/2020Sell3,323$3.35$11,132.05104,673View SEC Filing Icon  
9/2/2020Sell3,364$2.39$8,039.9697,099View SEC Filing Icon  
12/2/2019Sell14,272$1.53$21,836.1685,186View SEC Filing Icon  
See Full Table

Carsten Brunn Buying and Selling Activity at Selecta Biosciences

This chart shows Carsten Brunn's buying and selling at Selecta Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Selecta Biosciences Company Overview

Selecta Biosciences logo
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.06
Low: $0.88
High: $1.26

2 Week Range

Now: N/A

Volume

2,774,100 shs

Average Volume

979,585 shs

Market Capitalization

$136.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84